Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trelagliptin
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trelagliptin is a highly selective, long‐acting, orally active dipeptidyl peptidase‐4 (DPP‐4) inhibitor developed for the treatment of type 2 diabetes mellitus. It is notable as the first once-weekly oral DPP‐4 inhibitor, offering an alternative to daily dosing regimens. Trelagliptin works by inhibiting DPP‐4, an enzyme that degrades incretin hormones such as glucagon-like peptide 1 (GLP‑1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their activity and improving glycemic control. Clinical studies have demonstrated its efficacy in reducing hemoglobin A1c (HbA1c) with a safety profile comparable to other DPP‑4 inhibitors. Trelagliptin was developed by Takeda and approved in Japan and India for type 2 diabetes; development was discontinued in the US and EU due to regulatory cost considerations[2][4][5][8].
- Brand names
- ZafatekWedica
- Other names
- trelagliptin succinate
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on trelagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trelagliptin.